gms | German Medical Science

Kongress Medizin und Gesellschaft 2007

17. bis 21.09.2007, Augsburg

Non-chemotherapy drug-induced agranulocytosis: a systematic review of case reports

Meeting Abstract

Suche in Medline nach

  • Frank Andersohn - Bremer Institut für Präventionsforschung und Sozialmedizin (BIPS), Bremen
  • Christine Konzen - Institut für klinische Pharmakologie, Charité - Universitätsmedizin Berlin, Berlin
  • Edeltraut Garbe - Bremer Institut für Präventionsforschung und Sozialmedizin (BIPS), Bremen

Kongress Medizin und Gesellschaft 2007. Augsburg, 17.-21.09.2007. Düsseldorf: German Medical Science GMS Publishing House; 2007. Doc07gmds468

Die elektronische Version dieses Artikels ist vollständig und ist verfügbar unter: http://www.egms.de/de/meetings/gmds2007/07gmds468.shtml

Veröffentlicht: 6. September 2007

© 2007 Andersohn et al.
Dieser Artikel ist ein Open Access-Artikel und steht unter den Creative Commons Lizenzbedingungen (http://creativecommons.org/licenses/by-nc-nd/3.0/deed.de). Er darf vervielfältigt, verbreitet und öffentlich zugänglich gemacht werden, vorausgesetzt dass Autor und Quelle genannt werden.


Gliederung

Text

Background: Non-chemotherapy drug-induced agranulocytosis is a rare adverse drug reaction characterized by a decrease in peripheral neutrophil count to <500/µl due to immunological or cytotoxic mechanisms. Discontinuation of the causative drug is crucial to avoid continuation of hazardous drug exposure, but its identification may be a challenging problem in patients with poly-pharmacotherapy.

Objectives: To identify drugs definitely or probably related to agranulocytosis in published case reports and series. To analyze these case reports with respect to several clinical characteristics.

Methods: We performed a systematic review of English-language and German-language case reports found in MEDLINE (1966-2006) or EMBASE (1989-2006) or in bibliographies of retrieved articles. We abstracted details about cases and assessed causality between drug intake and agranulocytosis using World Health Organization causality assessment criteria.

Results: Causality assessments of 980 reported cases of agranulocytosis were: definite 56 (6%); probable 436 (44%); possible 481 (49%); and unlikely 7 (1%). 125 different drugs were definitely or probably related to agranulocytosis. Drugs for which >10 reports were available (carbimazole, clozapine, dapsone, dipyrone, methimazole, penicillin g, procainamide, propylthiouracil, rituximab, sulfasalazine, ticlopidine) accounted for >50% of definite or probable reports. Proportions of fatal cases decreased between 1966 and 2006. More cases with a neutrophil nadir <100/µl had fatal complications than those with a nadir > 100/µl (10% versus 3%, p<0.001). Cases reporting treatment with hematopoietic growth factors had a shorter median duration of neutropenia (8 days versus 9 days; p=0.015) and, among asymptomatic patients at diagnosis, had a lower proportion of infectious or fatal complications (14% treated versus 29% untreated; p=0.030) than those that did not report such treatment.

Conclusions: Several drugs can cause non-chemotherapy drug-induced agranulocytosis. Patients with a neutrophil count <100/µl are particularly at risk of developing life threatening complications. Associated mortality may be decreasing over time with the availability of better treatment including hematopoietic growth factors.